RDTCF (Rapid Dose Therapeutics) EBIT: $-2.19 Mil (TTM As of Nov. 2025)


RDTCF Rapid Dose Therapeutics Corp RDTCF
27 GF Score
Price $0.08
GF Value $0.30
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Rapid Dose Therapeutics EBIT?

Rapid Dose Therapeutics RDTCF -11.11% 27 EBIT is $-2.19 Mil as of Nov. 2025. GuruFocus rates RDTCF with a GF Score™ of 27/100 and a GF Value™ of $0.30 (Possible Value Trap). The stock has 4 warning signs investors should review.

Rapid Dose Therapeutics's earnings before interest and taxes (EBIT) for the three months ended in Nov. 2025 was $-0.49 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Nov. 2025 was $-2.19 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Rapid Dose Therapeutics's annualized ROC % for the quarter that ended in Nov. 2025 was -39.82%. Rapid Dose Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was -85.40%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Rapid Dose Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2025 was -14.43%.

Rapid Dose Therapeutics  (OTCPK:RDTCF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Rapid Dose Therapeutics's annualized ROC % for the quarter that ended in Nov. 2025 is calculated as:

ROC % (Q: Nov. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Aug. 2025 ) + Invested Capital (Q: Nov. 2025 ))/ count )
=-1.956 * ( 1 - 0% )/( (4.848 + 4.976)/ 2 )
=-1.956/4.912
=-39.82 %

where

Invested Capital(Q: Aug. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=3.08 - 3.221 - ( 0.007 - max(0, 5.712 - 0.723+0.007))
=4.848

Invested Capital(Q: Nov. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2.696 - 3.107 - ( 0.078 - max(0, 5.859 - 0.472+0.078))
=4.976

Note: The Operating Income data used here is four times the quarterly (Nov. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Rapid Dose Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Nov. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Aug. 2025  Q: Nov. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.956/( ( (2.356 + max(-2.538, 0)) + (2.225 + max(-2.754, 0)) )/ 2 )
=-1.956/( ( 2.356 + 2.225 )/ 2 )
=-1.956/2.2905
=-85.40 %

where Working Capital is:

Working Capital(Q: Aug. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.475 + 0.145 + 0.074) - (3.221 + 0.012 + -0.0010000000000003)
=-2.538

Working Capital(Q: Nov. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.143 + 0.127 + 0.083) - (3.107 + 0 + 0)
=-2.754

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Nov. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Rapid Dose Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Nov. 2025 )
=-2.185/15.147
=-14.43 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics EBIT Related Terms

Rapid Dose Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Rapid Dose Therapeutics's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapid Dose Therapeutics EBIT Chart

Rapid Dose Therapeutics Annual Data
Trend Sep16 Sep17 Sep18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.31 -6.57 -2.64 -2.70 -2.92

Rapid Dose Therapeutics Quarterly Data
Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.73 -0.94 -0.36 -0.39 -0.49

RDTCF vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Rapid Dose Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapid Dose Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Rapid Dose Therapeutics's EV-to-EBIT falls into.


RDTCF
27GF Score
Rapid Dose Therapeutics Corp RDTCF
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapid Dose Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.19 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-2.19 Mil mean?
Rapid Dose Therapeutics (RDTCF) has a EBIT of $-2.19 Mil as of Nov. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rapid Dose Therapeutics.
Is Rapid Dose Therapeutics' EBIT too high?
Rapid Dose Therapeutics' current EBIT is $-2.19 Mil. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' EBIT compare to VRTX and REGN?
Rapid Dose Therapeutics' EBIT of $-2.19 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Biotechnology company?
A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Rapid Dose Therapeutics. Rapid Dose Therapeutics's current EBIT is $-2.19 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current EBIT is $-2.19 Mil. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current EBIT is $-2.19 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?

Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued. The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30. GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.

Key valuation signals for RDTCF:

  • EBIT: $-2.19 Mil
  • GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
  • GF Score™: 27/100 with 4 warning signs

No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Rapid Dose Therapeutics Business Description

Other Exchanges DOSE:Canada
Address 1121 Walkers Line, Unit 3a, Burlington, ON, CAN, L7N 2G4
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score

Get the complete analysis for RDTCF

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.08
Price
$0.30
GF Value